Posted byOrthoEx Posted in
Posted on Nov 08, 2018

Gosselies, Belgium, 7 November 2018, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today provides a business update for the third quarter ended 30 September 2018.

Thomas Lienard, Chief Executive Officer of Bone Therapeutics, commented: “The third quarter was a period of significant clinical and strategic activity for Bone Therapeutics. We were delighted with the positive final readout in the Phase I/IIA delayed union study of the allogeneic bone cell therapy product ALLOB, which paves the way for the next stage of development. More recently, the promising results from our viscosupplement JTA-004 highlighted a complementary addition to our pipeline.

Our focus is now on progressing the clinical development of the ALLOB platform in delayed union fractures and lumbar spinal fusion and of JTA-004 in knee osteoarthritis, following the recommendation of the DSMB to discontinue the PREOB trial in hip osteonecrosis. This will be supported by our ongoing manufacturing optimisation process, which will help us to lay a strong foundation for our future commercialisation strategy.

Business highlights (incl. post period end)

  • In September, Bone Therapeutics announced a positive final readout in the Phase I/IIA delayed-union study of the allogeneic bone cell therapy product, ALLOB, adding to a growing body of clinical efficacy and safety data.
  • Simultaneously, the Company also announced an optimised manufacturing process for ALLOB to improve consistency, scalability, cost effectiveness and ease of use, which are critical for development and commercialisation in cell therapy. The Company plans to implement this optimised process for all future clinical development programmes involving ALLOB and recently received positive feedback on the quality control programme and non-clinical strategy for ALLOB from a Regulatory Agency for the optimisation of the manufacturing process.
  • Also in September, the Company presented preclinical in vitro and in vivo results at the 26th Annual Meeting of the European Orthopaedic Research Society (EORS) in which the scientific community acknowledged the potent bone-forming properties of its allogeneic platform.
  • In October, post period, Bone Therapeutics announced results for a first efficacy study in knee osteoarthritis with the enhanced viscosupplement JTA-004. The study showed that a single intra-articular injection of JTA-004 delivered higher pain reduction than the reference product, a leading viscosupplement. The results support the move to registration studies, broadening the Company’s advanced clinical pipeline.
  • In October, post period, Linda Lebon was appointed Chief Regulatory Officer, joining Company’s Executive Team. An industry veteran, Linda will play a crucial role in defining the regulatory pathway for clinical and development programmes.
  • On 6 November, post period, the Company announced that the Data and Safety Monitoring Board recommended the discontinuation of the PREOB Phase III trial in osteonecrosis of the hip, as the interim results suggested that it is unlikely that the primary objective will be achieved at the final analysis. For more information, please see additional press release dated 6 November 2018.

Financial highlights

  • Cash used in operating activities amounted to € 10.47 million for the first nine months of 2018, compared to € 10.14 million for the same period in 2017.
  • Operating loss amounted to € 8.96 million compared to € 8.76 million for the same period last year.
  • Net cash at the end of September 2018 amounted to € 8.41 million.


  • The Company’s immediate focus is on submitting a new clinical trial application (CTA) with the regulatory authorities to allow the start of a Phase IIB trial in delayed union with its allogeneic product, utilising the optimised production process. Bone Therapeutics is currently generating the non-clinical data required for the application and expects to submit the CTA for a multi-centre, randomised, controlled study in H2 2019.
  • Bone Therapeutics plans to report the top line results from 32 patients of the ALLOB Phase IIA spinal fusion study in mid-2019 after a 12-month follow-up.
  • Good cash management will remain a key priority, with a strong focus on net cash burn. The Company confirms the expected cash burn (excluding proceeds from financing) for the full year 2018 to be in the range of € 15-16 million, in line with previous guidance. Based on its current priorities, the Company expects to have sufficient cash to carry out its objectives until the end of Q3 2019.

About Bone Therapeutics

Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics’ technology is based on a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.

The Company’s primary clinical focus is ALLOB, an allogeneic “off-the-shelf” cell therapy platform derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. In addition, the Company also has JTA-004, a viscosupplement in development for the treatment of knee osteoarthritis.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at:


Bone Therapeutics SA
Thomas Lienard, Chief Executive Officer
Jean-Luc Vandebroek, Chief Financial Officer
Tel: +32 (0) 71 12 10 00

For Belgium Median Enquiries
Laure-Eve Monfort and Sabine Leclercq
Tel: +32 (0)2 290 90 93, +32 (0)2 290 90 91,

International Media Enquiries:
Consilium Strategic Communications
Amber Fennell, Jessica Hodgson, Hendrik Thys and Lindsey Neville
Tel: +44 (0) 20 3709 5701

For French Media and Investor Enquiries:
NewCap Investor Relations & Financial Communications
Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau
Tel: + 33 (0)1 44 71 94 94

For US Media and Investor Enquiries
Westwicke Partners
John Woolford
Tel: + 1 443 213 0506

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors` current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person`s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.